Loop Capital raised the price target for the CVS Health Corporation (NYSE:CVS) stock to ‘a Buy’. The rating was released on June 17, 2023, according to finviz. We previously noted in another research note published on May 27, 2023 by Bernstein that downgraded the stock from an Outperform to a Mkt perform with a price target of $112 for CVS stock. The research report from Deutsche Bank has downgraded the stock from Buy to Hold, with a price target set at $110. In their research brief published December 14, 2021, Goldman analysts initiated the CVS Health Corporation stock to Buy with a price target of $121.